e-ISSN:2320-1215 p-ISSN: 2322-0112

Rohit Mathur

Rohit Mathur

DR. Rohit Mathur

Department of Lymphoma/Myeloma

M.D. Anderson Cancer Center



M.D. Anderson Cancer Center, Houston Houston, TX Postdoctoral Research Fellow; Advisor: Felipe Samaniego 2011-2015 Targeting relapse and chemoresistance in Non-Hodgkin Lymphoma Diffuse large B-cell lymphoma  Epigenetic therapy: Demethylase inhibitors for improving treatment in diffuse large B-cell lymphoma (DLBCL). Methylation pattern increases with aggressiveness of tumor, therefore we have started investigating demethylases in regulation of DLBCL. Our current study suggests that JMJD3 could be a potential target for drug development in DLBCL. Mantle cell lymphoma  Stem cell signaling in lymphoma stem cells. We have found Wnt as an important pathway differentially up-regulated in Mantle cell lymphoma-initiating cells (MCL-ICs), which can be used to target MCL-ICs. Further, we are working to find unique markers on MCL-ICs.  Role of Long non coding RNA in chemoresistance of mantle cell lymphoma. We have elucidated function of long-non-coding RNAs in MCL-ICs. We have found that Fas-As1 expression could be responsible for resistance to ibrutinib.

Research Interest

Nuclear Medicine, cancer, lymphoma,